

Luca Potestio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9588903/publications.pdf>

Version: 2024-02-01

40
papers

760
citations

567281

15
h-index

713466

21
g-index

40
all docs

40
docs citations

40
times ranked

106
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to "Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre" by Sotiriou E <i>et al</i> . <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	40
2	Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 21-29.	2.4	21
3	Alitretinoin for the treatment of severe chronic eczema of the hands. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 159-167.	1.8	6
4	Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	28
5	New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma. <i>Advances in Therapy</i> , 2022, 39, 1164-1178.	2.9	29
6	Dermatophytid evaluated by <i>in vivo</i> reflectance confocal microscopy: a new approach?. <i>International Journal of Dermatology</i> , 2022, , .	1.0	2
7	Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2560-2564.	2.2	43
8	Letter to the editor regarding the article "Oguz Topal I, Kara Polat A, ZindancÄ± Å°, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. <i>J Cosmet Dermatol</i> . 2021;10.1111/jocd.14610." <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 880-882.	1.6	2
9	Letter to the editor submitted in response to "Should the presence of psoriatic arthritis change how we manage psoriasis?". <i>Journal of Dermatological Treatment</i> , 2022, , 1-3.	2.2	3
10	New-onset lichen planus arising after COVID-19 vaccination. <i>Dermatologic Therapy</i> , 2022, 35, e15374.	1.7	27
11	Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas. <i>Oncologist</i> , 2022, 27, e533-e533.	3.7	3
12	Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?. <i>Dermatologic Therapy</i> , 2022, 35, e15423.	1.7	3
13	Clinical, trichoscopic and <i>in vivo</i> reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	3
14	The effects of dupilumab treatment on general health-related work productivity of adult atopic patients. <i>Italian Journal of Dermatology and Venereology</i> , 2022, , .	0.2	0
15	Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. <i>Journal of Clinical Medicine</i> , 2022, 11, 1511.	2.4	34
16	Teledermatology: A useful tool also after COVID-19 era?. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 2309-2310.	1.6	33
17	A case of acne fulminans successfully treated with photodynamic therapy. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2022, 38, 401-403.	1.5	4
18	Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. <i>Dermatologic Therapy</i> , 2022, 35, e15524.	1.7	43

#	ARTICLE	IF	CITATIONS
19	Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1497-1498.	2.4	37
20	Letter to the editor regarding article "Gu L, Diaz SM, Lipner SR. Retrospective study of acne telemedicine and in-person visits at an academic center during the COVID-19 pandemic. <i>J Cosmet Dermatol</i> . 2022;21(1):36-38." <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 6441-6442.	1.6	0
21	A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis. <i>Dermatologic Therapy</i> , 2022, 35, e15588.	1.7	15
22	Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2813-2820.	2.2	57
23	Maskne prevalence and risk factors during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	5
24	The Treatment of Advanced Melanoma: Therapeutic Update. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6388.	4.1	41
25	Reply to "Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study"™ by Bawane J <i>et al</i> .. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	27
26	Treating psoriasis in the elderly: biologics and small molecules. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1503-1520.	3.1	30
27	Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectance confocal microscopy evaluation. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	2
28	Dupilumab for the treatment of adult atopic dermatitis in special populations. <i>Journal of Dermatological Treatment</i> , 2022, 33, 3028-3033.	2.2	23
29	Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	28
30	Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops. <i>Contact Dermatitis</i> , 2021, 85, 382-384.	1.4	2
31	Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?. <i>Dermatologic Therapy</i> , 2021, 34, e15030.	1.7	27
32	Alcohol flushing during dupilumab therapy: An emerging adverse event. <i>Dermatologic Therapy</i> , 2021, 34, e15064.	1.7	0
33	Scabies outbreak during COVID-19: an Italian experience. <i>International Journal of Dermatology</i> , 2021, 60, 1307-1308.	1.0	34
34	Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. <i>Dermatologic Therapy</i> , 2021, 34, e15120.	1.7	25
35	New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?. <i>Biomedicines</i> , 2021, 9, 1482.	3.2	31
36	Letter to the editor regarding article "Yalici A, Armagan B, Tabak GH, Dogan G, Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. <i>J Cosmet Dermatol</i> . 2021;00:1-5." <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 4073-4075.	1.6	6

#	ARTICLE	IF	CITATIONS
37	Letter to the editor submitted in response to "Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study". Journal of Dermatological Treatment, 0, , 1-2.	2.2	0
38	Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis: Targets and Therapy, 0, Volume 12, 127-137.	2.2	24
39	Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study. Psoriasis: Targets and Therapy, 0, Volume 12, 199-204.	2.2	7
40	Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study. Psoriasis: Targets and Therapy, 0, Volume 12, 205-212.	2.2	15